NASH is characterized by hepatocellular injury accompanied by steatosis, inflammation and fibrosis. SKLB023 as a potent iNOS inhibitor, suppressed the activation of TGF-β/Smad signaling pathway by blocking iNOS expression to attenuate liver fibrosis in MCD diet-induced mice.